Australian scientists have discovered how the immune system can control melanoma, a mechanism which could be used to enhance cancer treatments.
Published today in Nature, Peter Doherty Institute for Infection and Immunity (Doherty Institute) and Telethon Kids Institute researchers investigated the role of a particular immune cell, tissue-resident memory T (TRM) cells, in controlling melanoma.
TRM cells were able to control the tumour in the mice for the life of the animal, which is likely to equate to decades of protection in humans.
University of Melbourne PhD student, Simone Park from the Doherty Institute, created an imaging model to study TRM cells’ and melanoma in a mouse model.
“Using a special microscope, we could see individual melanoma cells sitting in the skin of the mouse, and could watch the T cells move through the skin, find the melanoma cells and control the growth of those cells,” Ms Park explained.
One of the main issues for cancer patients is that there is always a risk that the tumour can come back years later, after surgery or chemotherapy.
Previous research has shown that small numbers of cancer cells persist in the body after treatment and that the immune system probably keeps the cancer cells under control but this study in mice could study the immune system directly. This is work that could never be done in people.
“I was able to see through moving images that these TRM cells are important for maintaining the control of the tumour cells; if you remove the TRM cells you have a break in that control and the cancer can start to grow back again,” Ms Park said.
“If you could make more of these TRM cells through immunotherapies, or enhance the activity of those that are already there in some way, you could boost anti-tumour immunity.”
Senior author on the paper, University of Melbourne Associate Professor Thomas Gebhardt, Laboratory Head at the Doherty Institute, said an increase of TRM cells has already been associated with better outcomes in cancer patients, but the way they work to suppress tumours has remained unknown.
“The principal of cutting-edge immunotherapies currently in clinical practise is that they generate a T-cell response. But if we can hone in on one type of T-cell – the TRM cells specifically, we could have an even bigger impact on stopping cancers from coming back,” Associate Professor Gebhardt said.
“We now have a much better understanding of which T-cells are important in controlling skin cancers and how those cells are working but there is still much more work to do to make these cells work even better,” Associate Professor Gebhardt said.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Doctor who spent career researching melanoma dies from the disease after spotting changes to a mole on her neckon January 10, 2020 at 8:38 am
A doctor who spent her career investigating the causes and treatment options for melanoma has died from the disease after noticing changes to a mole on her neck. Dr Sharon Hutchinson, who worked as a ...
- Moffitt researchers identify molecular characteristics of leptomeningeal melanoma metastaseson January 10, 2020 at 7:55 am
TAMPA, Fla. - Patients with advanced melanoma who develop metastases in the leptomeninges, the fluid filled membranes surrounding the brain and spinal cord, have an extremely dismal prognosis. Most ...
- Metastatic Melanoma Drug Market Emerging Analysis, Future Growth And Business Opportunities 2026on January 9, 2020 at 11:08 pm
As the competition soars in the global Metastatic Melanoma Drug market, an increasing number of companies are looking exclusive insights into the prevailing trends in the market. Ameco Research study ...
- AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanomaon January 9, 2020 at 9:19 am
Cutaneous malignant melanoma (CMM) is the deadliest form of skin cancer and clinically challenging due to its propensity to develop therapy resistance. Reactive oxygen species (ROS) can induce DNA ...
- Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cellson January 9, 2020 at 2:30 am
The study population consists of 12 melanoma patients and 6 healthy donors (HDs) used as controls. Selected characteristics of all subjects are listed in STable 1. Age at blood draw did not differ ...
- Metastatic Uveal Melanoma Thereapeutics Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2027on January 8, 2020 at 5:19 pm
Ameco Research added new research report to its vast database titled "Global Metastatic Uveal Melanoma Thereapeutics Market 2019" which provides extensive and highly detailed information on the key ...
- Let's Talk About Melanomaon January 8, 2020 at 8:08 am
Whether you’ve just been diagnosed or worry you could have melanoma, you’re probably nervous, confused, and likely scared. We get it: Melanoma is a form of skin cancer that can be life-threatening.
- Melanoma Immunotherapy Enhanced by Targeting Treg Cell Control Proteinon January 8, 2020 at 5:19 am
For some people with advanced melanoma, such treatment has extended survival from months, to years. However, therapy is only effective in about 40% of people with advanced melanoma. Ze’ev Ronai, Ph.D.
- Melanoma can affect all ages: education, protection importanton January 7, 2020 at 8:35 am
Melanoma can affect anyone, even the young. Education and protection are critical, accordng to a Houston dermatologist.
- Study reveals a new approach to enhancing response to immunotherapy in melanomaon January 7, 2020 at 2:01 am
For some people with advanced melanoma, a deadly skin cancer, the treatment has extended survival to years instead of months. However, the treatment only works for about 40% of people with advanced ...
via Bing News